Yet, the TGFβ pathway appears intact and functional in the majority of CRC specimens [27], and comprehensive transcriptome analyses provided evidence for active TGFβ signaling also in cancer cells [28, 29], including the consensus molecular subtype 4 (CMS4) of human CRC, which is the CMS with the poorest prognosis [29, 30]. This evidence concerns the gene TGFB1 and colorectal carcinoma.